Key terms
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest JAGX news
Apr 22
4:35pm ET
Jaguar Health files $75M mixed securities shelf
Apr 19
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Apr 18
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Apr 18
8:44am ET
Jaguar Health appoints Catherine Miller Collis as SVP, growth strategy
Apr 16
8:42am ET
Jaguar Health enters in-license agreement with Venture Life Group for Gelclair
Apr 12
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Apr 09
5:43pm ET
Jaguar Health’s Strategic Moves to Regain Nasdaq Compliance
Apr 08
8:57am ET
Jaguar Health granted extension to regain Nasdaq compliance
Apr 01
8:27am ET
Jaguar Health reports 2023 EPS ($1.79) vs. ($36.18) last year
Mar 20
8:38am ET
Jaguar Health signs term sheet for license, commercialization agreement
Mar 06
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Mar 04
10:50am ET
Biotech Alert: Searches spiking for these stocks today
Feb 23
8:37am ET
Jaguar Health receives hearing on Nasdaq listing compliance
Feb 16
4:22pm ET
Jaguar Health Risks Nasdaq Delisting Over Low Stock Price
Feb 15
8:46am ET
Jaguar announces FDA agreement with clinical trial protocol for Canalevia-CA1
Feb 12
8:38am ET
Jaguar Health submits Orphan Drug Designation application to FDA for crofelemer
Jan 30
8:52am ET
Magdalena Biosciences announces results from preclinical study in mice in Brazil
Jan 25
8:45am ET
Jaguar Health announces publication of study in PLOS ONE using crofelemer
Apr 22
8:45am ET
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
Apr 18
8:30am ET
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Apr 16
8:30am ET
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Apr 09
4:15pm ET
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Apr 08
8:30am ET
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Apr 02
8:50am ET
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Apr 01
8:00am ET
Jaguar Health Reports 2023 Financial Results
Mar 27
8:30am ET
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Mar 20
8:30am ET
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
JAGX Financials
Key terms
Ad Feedback
JAGX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
JAGX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
